Date
- Monday, 04 November 2019
Location
- European Medicines Agency, Amsterdam, the Netherlands
The European Medicines Agency organised a meeting to discuss lessons learnt from recent cases of sartan (angiotensin receptor blockers) medicines containing N-nitrosamine impurities. It discussed how to better prevent and manage cases of medicines with N-nitrosamine impurities in the future.
The meeting brought together patients and healthcare professional organisations, industry associations and European Union and international regulatory authorities.